Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.
Jun ChenLu XiaLi LiuQingnian XuYun LingDan HuangWei HuangShuli SongShuibao XuYingzhong ShenHongzhou LuPublished in: Open forum infectious diseases (2020)
Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated.